Cited by 91Sleep and Work-Related FatigueSleep and Wakefulness ResearchNeuroethics, Human Enhancement, Biomedical Innovations

An Overview of the Clinical Uses, Pharmacology, and Safety of Modafinil

Open access
Murillo-Rodríguez, Eric, Barciela Veras, André, Barbosa Rocha, Nuno, Budde, Henning, Machado, Sérgio·2018·ACS Chemical Neuroscience

Abstract

Modafinil (MOD) is a wakefulness-inducing compound prescribed for treatment of excessive daytime sleepiness as a consequence of sleep disturbances such as shift work sleep disorder, obstructive sleep apnea, restless leg syndrome, or narcolepsy. While providing effective results in patients with sleepiness, MOD also produces positive outcomes in the management of fatigue associated with different conditions including depression, cancer, or tiredness in military personnel. Although there is clear evidence of the stimulant effects of MOD, current data also show that administration of this drug apparently induces positive neurobiological effects, such as improvement in memory. However, serious concerns have been raised since some reports have suggested MOD dependence. Taken together, these findings highlight the need to characterize the changes induced by MOD which have been observed in several neurobiological functions. Moreover, further work should follow up on the likely long-term effects of this drug if used for treatment of drowsiness and tiredness. Here, we review and summarize recent findings of the medical uses of MOD in the management of sleepiness and fatigue associated with depression or cancer as well as exhaustion in military personnel. We also discuss the available literature related with the cognitive enhancing properties of this stimulant, as well as what is known and unknown about MOD addiction.

Integrity signals

Registry

Crossref · 10.1021/acschemneuro.7b00374

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Evidence for topiramate in cocaine use disorder is mixed; a meta-analysis showed higher continuous stimulant abstinence over three weeks with topiramate versus placebo.

    “The evidence for topiramate in cocaine use disorder outcomes is mixed; a meta-analysis demonstrated a higher rate of continuous stimulant abstinence over three weeks with topiramate versus placebo.114”
  • These studies generally noted a large beneficial effect of pharmacotherapy for both preexisting and stimulant-induced psychosis, as well as preexisting and stimulant-induced mania.

    “These studies generally noted a large beneficial effect of pharmacotherapy for both preexisting and stimulant-induced psychosis, as well as preexisting and stimulant-induced mania.”
  • Almost all evidence for treating symptoms of psychosis from systematic reviews and meta-analyses is based on stimulant-induced or unspecified causes of psychosis.

    “Almost all evidence for treating symptoms of psychosis from systematic reviews and meta-analyses is based on stimulant-induced or unspecified causes of psychosis.114,117,119,[150][151][152][153][154][155]”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Murillo-Rodríguez, E., Barciela Veras, A., Barbosa Rocha, N., Budde, H., & Machado, S.
Affiliations
  • Laboratorio de Neurociencias Moleculares e Integrativas, Escuela de Medicina División Ciencias de la Salud, Universidad Anáhuac Mayab, 97310 Mérida, Yucatán, México
  • Intercontinental Neuroscience Research Group, Yucatán, México
  • Reykjavík University (IS)
Venue
ACS Chemical Neuroscience
Published
2017-12-04
Volume
9
Issue
2
Pages
151-158
ISSN
1948-7193 (ISSN-L)
OpenAlex
W2767299082
Cited by
91
References
4
Citations by year
2026: 4 · 2025: 7 · 2024: 9 · 2023: 13 · 2022: 16 · 2021: 16 · 2020: 11 · 2019: 12 · 2018: 3
FWCI
1.13
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • ACS Chemical Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Funders
  • Consejo Nacional de Ciencia y Tecnolog?a (CN-17-19)
  • University of California Institute for Mexico and the United States
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and Work-Related Fatigue
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Neuroethics, Human Enhancement, Biomedical Innovations
Keywords
modafinil, wakefulness-promoting agents, excessive daytime sleepiness, shift work disorder, obstructive sleep apnea, restless legs syndrome, narcolepsy, fatigue, depression, cancer, military personnel, cognitive enhancement, memory, drug addiction, stimulants, pharmacology, drug safety
MeSH terms
Modafinil, Animals, Benzhydryl Compounds, Cognition, Humans, Sleep, Wakefulness-Promoting Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review